New Alzheimer’s drug LM11A-31 shows promise in slowing disease progression in clinical trial

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) Across the world, fund­ing for dig­i­tal health

Ab­b­Vie will end the last parts of its CD47 agree­ment with I-Mab, the Mary­land and Shang­hai biotech dis­closed in a Fri­day SEC fil­ing. The Chica­go-area

Less than a year af­ter the end of a PD-1 deal with No­var­tis, BeiGene is look­ing at new part­ner­ships that could bring in new as­sets